Increased potentiation of 5-fluorouracil induced thymidylate synthase inhibition by 5,10-methylenetetrahydrofolate (arfolitixorin) compared to leucovorin in patients with colorectal liver metastases; The Modelle-001 Trial

Autor: Helena Taflin, Elisabeth Odin, Göran Carlsson, Bengt Gustavsson, Oskar Hemmingsson, Yvonne Wettergren, Krzysztof Urbanowicz, Jacek Turyn, Ryszard T. Smolenski, Godefridus J. Peters

Publikováno v: BJC Reports, Vol 2, Iss 1, Pp 1-8 (2024)

Abstract Background 5-Fluorouracil (5-FU) is a cornerstone in treatment of colorectal cancer (CRC) and is usually combined with leucovorin (LV) to enhance the antitumour effect by increase thymidylate synthase (TS) inhibition, the key target enzyme f

Externí odkaz: https://doaj.org/article/dbe0b6d65b514af3a3a23fa46aa693b6

Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma

Autor: I Gede Putu Supadmanaba, Giulia Mantini, Ornella Randazzo, Mjriam Capula, Ittai B. Muller, Stella Cascioferro, Patrizia Diana, Godefridus J. Peters, Elisa Giovannetti

Publikováno v: Epigenetics, Vol 17, Iss 4, Pp 381-404 (2022)

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers because of diagnosis at late stage and inherent/acquired chemoresistance. Recent advances in genomic profiling and biology of this disease have not yet been translated to a rel

Externí odkaz: https://doaj.org/article/95e67049e83d471fb22f4dea5968ac00

Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models

Autor: Pei Pei Che, Alessandro Gregori, Omidreza Firuzi, Max Dahele, Peter Sminia, Godefridus J. Peters, Elisa Giovannetti

Publikováno v: Experimental Hematology & Oncology, Vol 9, Iss 1, Pp 1-3 (2020)

Abstract Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor response to chemo- and (modest-dose conventionally fractionated) radio-therapy. Emerging evidence suggests that pancreatic stellate cells (PSCs) secrete deoxycytidine, which confe

Externí odkaz: https://doaj.org/article/3b876c3d1a844d15b44488633c337b48

The Influence of Mitochondrial Energy and 1C Metabolism on the Efficacy of Anticancer Drugs: Exploring Potential Mechanisms of Resistance

Autor: Godefridus J. Peters, Marika Franczak, Isabel Toenshoff, Gerrit Jansen, Ryszard T. Smolenski, Elisa Giovannetti

Publikováno v: Franczak, M, Toenshoff, I, Jansen, G, Smolenski, R T, Giovannetti, E & Peters, G J 2023, ' The Influence of Mitochondrial Energy and 1C Metabolism on the Efficacy of Anticancer Drugs : Exploring Potential Mechanisms of Resistance ', Current Medicinal Chemistry, vol. 30, no. 11, pp. 1209-1231 . https://doi.org/10.2174/0929867329666220401110418

Abstract: Mitochondria are the main energy factory in living cells. To rapidly proliferate and metastasize, neoplastic cells increase their energy requirements. Thus, mitochondria become one of the most important organelles for them. Indeed, much res

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f40dbd51ebd58d66aad7162853300939
https://doi.org/10.2174/0929867329666220401110418

Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro

Autor: Godefridus J. Peters, Frank P. A. van Gemert, Ietje Kathmann, Guru Reddy, Saskia A. G. M. Cillessen, Gerrit Jansen

Publikováno v: Frontiers in Cell and Developmental Biology, Vol 8 (2020)

Pralatrexate (Folotyn; PLX) and belinostat (Beleodaq; BLS) are registered for the treatment of patients with peripheral T-cell lymphoma (PTCL) and are being considered for other lymphomas. In this study we investigated whether BLS had the ability to

Externí odkaz: https://doaj.org/article/3e3291e8ac454216bc476996dc1f37dc